These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 18641985)

  • 41. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting.
    Kurzrock R; Kantarjian HM; Cortes JE; Singhania N; Thomas DA; Wilson EF; Wright JJ; Freireich EJ; Talpaz M; Sebti SM
    Blood; 2003 Dec; 102(13):4527-34. PubMed ID: 12947010
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome: a pilot study.
    Fukuhara T; Miyake T; Maekawa I; Kurosawa M; Suzuki S; Noto S; Mori A; Chiba K; Toyoshima T; Hirano T; Morioka M; Tsutsumi Y; Okabe M; Kakinoki Y
    Int J Hematol; 2000 Jun; 71(4):366-71. PubMed ID: 10905057
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study.
    Martinelli G; Oehler VG; Papayannidis C; Courtney R; Shaik MN; Zhang X; O'Connell A; McLachlan KR; Zheng X; Radich J; Baccarani M; Kantarjian HM; Levin WJ; Cortes JE; Jamieson C
    Lancet Haematol; 2015 Aug; 2(8):e339-46. PubMed ID: 26688487
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oral idarubicin as treatment for advanced myelodysplastic syndrome.
    Lowenthal RM; Lambertenghi-Deliliers G
    Haematologica; 1991; 76(5):398-401. PubMed ID: 1806444
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes.
    Klimek VM; Fircanis S; Maslak P; Guernah I; Baum M; Wu N; Panageas K; Wright JJ; Pandolfi PP; Nimer SD
    Clin Cancer Res; 2008 Feb; 14(3):826-32. PubMed ID: 18245545
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A limited number of 5-azacitidine cycles can be effective treatment in MDS.
    Müller-Thomas C; Schuster T; Peschel C; Götze KS
    Ann Hematol; 2009 Mar; 88(3):213-9. PubMed ID: 18696067
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity.
    Adjei AA; Erlichman C; Davis JN; Cutler DL; Sloan JA; Marks RS; Hanson LJ; Svingen PA; Atherton P; Bishop WR; Kirschmeier P; Kaufmann SH
    Cancer Res; 2000 Apr; 60(7):1871-7. PubMed ID: 10766174
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A phase I/II study of oral clofarabine plus low-dose cytarabine in previously treated acute myeloid leukaemia and high-risk myelodysplastic syndrome patients at least 60 years of age.
    Buckley SA; Mawad R; Gooley TA; Becker PS; Sandhu V; Hendrie P; Scott BL; Wood BL; Walter RB; Smith K; Dean C; Estey EH; Pagel JM
    Br J Haematol; 2015 Aug; 170(3):349-55. PubMed ID: 25854284
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular mechanisms of the progression of myelodysplastic syndrome to secondary acute myeloid leukaemia and implication for therapy.
    Dan C; Chi J; Wang L
    Ann Med; 2015 May; 47(3):209-17. PubMed ID: 25861829
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prevalence of N-ras mutations in children with myelodysplastic syndromes and acute myeloid leukemia.
    Lübbert M; Mirro J; Kitchingman G; McCormick F; Mertelsmann R; Herrmann F; Koeffler HP
    Oncogene; 1992 Feb; 7(2):263-8. PubMed ID: 1549347
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure.
    Thepot S; Boehrer S; Seegers V; Prebet T; Beyne-Rauzy O; Wattel E; Delaunay J; Raffoux E; Hunault M; Jourdan E; Chermat F; Sebert M; Kroemer G; Fenaux P; Adès L;
    Leuk Res; 2014 Dec; 38(12):1430-4. PubMed ID: 25449687
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mutation of Ki-ras and N-ras oncogenes in myelodysplastic syndromes.
    Lyons J; Janssen JW; Bartram C; Layton M; Mufti GJ
    Blood; 1988 Jun; 71(6):1707-12. PubMed ID: 3285909
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance).
    Gupta P; Mulkey F; Hasserjian RP; Sanford BL; Vij R; Hurd DD; Odenike OM; Bloomfield CD; Owzar K; Stone RM; Larson RA;
    Invest New Drugs; 2013 Oct; 31(5):1311-20. PubMed ID: 23700288
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Long-term effects of androgen combined with low dose all-trans-retinoic acid on myelodysplastic syndrome: follow-up of 60 cases].
    Guan M; Chen SC; Ge CW
    Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(13):919-22. PubMed ID: 19671296
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Treatment of myelodysplastic syndrome by combined traditional Chinese medicine and Western medicine therapy].
    Wang XT; He HT
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 1993 Jul; 13(7):410-2, 388. PubMed ID: 8251723
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Analyzing transformation of myelodysplastic syndrome to secondary acute myeloid leukemia using a large patient database.
    Shukron O; Vainstein V; Kündgen A; Germing U; Agur Z
    Am J Hematol; 2012 Sep; 87(9):853-60. PubMed ID: 22674538
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
    Cortes J
    Clin Lymphoma; 2003 Aug; 4 Suppl 1():S30-5. PubMed ID: 14556673
    [TBL] [Abstract][Full Text] [Related]  

  • 58. RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up.
    Padua RA; Guinn BA; Al-Sabah AI; Smith M; Taylor C; Pettersson T; Ridge S; Carter G; White D; Oscier D; Chevret S; West R
    Leukemia; 1998 Jun; 12(6):887-92. PubMed ID: 9639416
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of myelodysplastic syndromes with orally administered 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate.
    Ohno R; Tatsumi N; Hirano M; Imai K; Mizoguchi H; Nakamura T; Kosaka M; Takatsuki K; Yamaya T; Toyama K
    Oncology; 1991; 48(6):451-5. PubMed ID: 1749580
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A pilot study of bendamustine in elderly patients with high-risk MDS and AML.
    Strupp C; Knipp S; Hartmann J; Gattermann N; Haas R; Germing U
    Leuk Lymphoma; 2007 Jun; 48(6):1161-6. PubMed ID: 17577779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.